Ulcerative Colitis Stocks List

Ulcerative Colitis Stocks Recent News

Date Stock Title
May 10 ABBV Ironwood (IRWD) Q1 Earnings & Revenues Fall Shy of Estimates
May 10 IMMX Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
May 10 ABBV 3 Rock-Solid Dividend Stocks That Are Ideal for Retirees
May 10 FBIO Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
May 9 HCM Spectrum Brands Posts Upbeat Results, Joins AerSale, Sinclair, ICU Medical And Other Big Stocks Moving Higher On Thursday
May 9 LXRX Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024
May 9 MCRB Seres Therapeutics First Quarter 2024 Earnings: US$0.28 loss per share (vs US$0.56 loss in 1Q 2023)
May 9 ABBV Q1 2024 Regenxbio Inc Earnings Call
May 9 MCRB Seres Therapeutics Inc (MCRB) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...
May 8 MCRB Seres Therapeutics Reports Q1 2024 Earnings: Surpasses Revenue Estimates
May 8 ABBV QULIPTA™ (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults
May 8 MCRB Seres Therapeutics GAAP EPS of -$0.27 beats by $0.07
May 8 MCRB Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
May 8 PTGX Protagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic Collaborations
May 7 PTGX Protagonist GAAP EPS of $3.26, revenue of $254.95M
May 7 ABBV Teva Earnings Are Soon. What Could Keep the Stock Gains Going.
May 7 PTGX Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event
May 7 PTGX Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 7 ABBV 15 Best S&P 500 Dividend Stocks To Buy Now
May 7 MCRB Seres Therapeutics Q1 2024 Earnings Preview
Ulcerative Colitis

Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon and rectum. The primary symptoms of active disease are abdominal pain and diarrhea mixed with blood. Weight loss, fever, and anemia may also occur. Often, symptoms come on slowly and can range from mild to severe. Symptoms typically occur intermittently with periods of no symptoms between flares. Complications may include megacolon, inflammation of the eye, joints, or liver, and colon cancer.The cause of UC is unknown. Theories involve immune system dysfunction, genetics, changes in the normal gut bacteria, and environmental factors. Rates tend to be higher in the developed world with some proposing this to be the result of less exposure to intestinal infections, or to a Western diet and lifestyle. The removal of the appendix at an early age may be protective. Diagnosis is typically by colonoscopy with tissue biopsies. It is a kind of inflammatory bowel disease (IBD) along with Crohn's disease and microscopic colitis.Dietary changes, such as maintaining a high-calorie diet or lactose-free diet, may improve symptoms. Several medications are used to treat symptoms and bring about and maintain remission, including aminosalicylates such as mesalazine or sulfasalazine, steroids, immunosuppressants such as azathioprine, and biologic therapy. Removal of the colon by surgery may be necessary if the disease is severe, does not respond to treatment, or if complications such as colon cancer develop. Removal of the colon and rectum can cure the disease.Together with Crohn's disease, about 11.2 million people were affected as of 2015. Each year it newly occurs in 1 to 20 per 100,000 people, and 5 to 500 per 100,000 individuals are affected. The disease is more common in North America and Europe than other regions. Often it begins in people aged 15 to 30 years, or among those over 60. Males and females appear to be affected in equal proportions. It has also become more common since the 1950s. Together, ulcerative colitis and Crohn's disease affect about a million people in the United States. With appropriate treatment the risk of death appears the same as that of the general population. The first description of ulcerative colitis occurred around the 1850s.

Browse All Tags